ALISO VIEJO, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Clarient, Inc. has been named to Deloitte's prestigious Technology Fast 50 program for Orange County, a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in the area by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2001 to 2005.
This year's Orange County Technology Fast 50 program is co-presented by Deloitte & Touche USA LLP and Porsche Motorsport, Continental Airlines, DLD Insurance, McDermott & Bull, Comerica, Stradling Yocca Carlson & Rauth, Cresa Partners and Merrill Corporation, in association with AeA and the Technology Council of Southern California.
Clarient's CEO Ronnie Andrews credits a new corporate vision and the tireless work of the entire Clarient team with the company's strong revenue growth over the past few years. Andrews said, "Our transition to diagnostic services, focused on cancer and those who fight that disease, has unleashed tremendous growth in the past two years as our marketplace has responded favorably. We aim to continue this trajectory of growth in the coming years as we continue to help physicians and pharmaceutical companies find better and more accurate ways of diagnosing and treating cancer. This award is a tribute to the entire Clarient team and all of those we serve."
Clarient's increase in revenues of 312 percent from 2001 to 2005 placed the company in the top ten in the Technology Fast 50 for Orange County.
"To rank on Deloitte's Technology Fast 50, companies must have phenomenal revenue growth over five years," said Rick Rayson, Managing Partner, Deloitte & Touche LLP in Orange County. "Clarient has proven to be one of the fast-growth success stories in Orange County, and we applaud its dedication to making its vision a reality."
To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.
Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit www.fast500.com.
About Clarient Inc.
Clarient (www.clarientinc.com) combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide technologies, services and the critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.
The company was formed in 1996 to develop and market the ACIS(R) Automated Cellular Imaging System(TM), an important advance in slide-based testing. The rise of individualized medicine as the new direction in oncology led the company in 2004 to expand its business model to provide the full range of leading diagnostic technologies such as flow cytometry and molecular testing in-house, creating a state-of-the-art commercial cancer laboratory and providing the most advanced oncology testing and drug development services available. For more information, visit www.clarientinc.com, a Safeguard partner company.
About Safeguard
Safeguard Scientifics, Inc. builds value in high-growth, revenue-stage information technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. The company participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. For more information about Safeguard, please visit www.safeguard.com.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte", "Deloitte & Touche", "Deloitte Touche Tohmatsu" or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.
Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.
The statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the Company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to, the Company's ability to obtain additional financing on acceptable terms or at all, and other risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to instrument placements, new contracts for placements, revenues and results of operations may not be indicative of future results for the reasons set forth above.
The company does not assume any obligation to update any forward-looking statements or other information contained in this document.
Investors: Clarient, Inc.: Matt Clawson Charlene Lu Allen & Caron, Inc. (949) 425-5700 (949) 474-4300
Clarient, Inc.CONTACT: Investors, Matt Clawson of Allen & Caron, Inc., +1-949-474-4300,for Clarient, Inc.; or Charlene Lu of Clarient, Inc., +1-949-425-5700
